Proportions achieving day 42 antibody titer of 40 or greater or seroconversion ( a minimum 4-fold increase to titer 40 ) with the hemagglutination inhibition assay ; vaccine-related serious adverse events through month 13 ; and solicited postvaccination symptoms through day 7 .